

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

J. Kevin Judice et al.

CYCLODEXTRIN

Title:

PHARMACEUTICAL COMPOSITIONS CONTAINING A GLYCOPEPTIDE ANTIBIOTIC

Docket No.:

1343.016US1

Serial No.: 09/846,893 Due Date: N/A

Filed:

May 1, 2001

Group Art Unit: 1614

Examiner:

Unknown

Commissioner for Patents Washington, D.C. 20231

We are transmitting herewith the following attached items (as indicated with an "X"):

A return postcard. <u>X</u>

X An Information Disclosure Statement (1 p.), Form 1449 (2 p.), and copies of 37 cited references.

Please consider this a PETITION FOR EXTENSION OF TIME for sufficient number of months to enter these papers and please charge any additional required fees or credit overpayment to Deposit Account No. 19-0743.

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.

P.O. Box 2938, Minneapolis, MN 55402 (612-373-6900)

Atty: Robert J. Harris, Ph.D.

Reg. No. 37,346

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231, on this Ath day of November, 2001.

Alisia G. Dunbar

Name

Customer Number 21186

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.

P.O. Box 2938, Minneapolis, MN 55402 (612-373-6900)

(GENERAL)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Filed:

J. Kevin Judice et al.

Serial No.:

09/846,893

May 1, 2001

Examiner: Unknown

Group Art Unit: 1614

Docket: 1343.016US1

PHARMACEUTICAL COMPOSITIONS CONTAINING A GLYCOPEPTIDE ANTIBI

AND A CYCLODEXTRIN

INFORMATION DISCLOSURE STATEMENT

istant Commissioner for Patents Washington, D.C. 20231

In compliance with the duty imposed by 37 C.F.R. § 1.56, and in accordance with 37 C.F.R. §§ 1.97 et. seq., the enclosed materials are brought to the attention of the Examiner for consideration in connection with the above-identified patent application.

Applicants are submitting herewith EP 149197 with an English abstract. Applicants submit that the English abstract is a concise explanation of the relevancy of EP 149197 as it is presently understood and as required under 37 C.F.R. 1.98(a)(3). Accordingly, the Examiner is respectfully requested to acknowledge consideration of the European patent. For the Examiner's convenience, EP 149197 has been listed on the enclosed Form 1449 and a copy of said patent and it's English abstract are enclosed herewith.

Applicants respectfully request that this Information Disclosure Statement be entered and the documents listed on the attached Form 1449 be considered by the Examiner and made of record. Pursuant to the provisions of MPEP 609, Applicants further request that a copy of the 1449 form, initialled by the Examiner to indicate that all listed citations have been considered, be returned with the next official communication.

Under 37 C.F.R. §1.97(b)(3), it is believed that no fee or certificate is required with this Information Disclosure Statement. However, if an Office Action on the merits has been mailed, the Commissioner is hereby authorized to charge any additional fees or credit any overpayment to Account No. 19-0743.

The Examiner is invited to contact the Applicants' Representative at the below-listed telephone number if there are any questions regarding this communication.

Respectfully submitted,

J. KEVIN JUDICE ET AL.

By their Representatives,

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.

P.O. Box 2938

Minneapolis, MN 55402

(612) 359-3265

Robert J. Harris, Ph.D.

Reg. No. 37,346

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: Commissioner of Patents, Washington, D.C. 20231, on this day of November, 2001.

<u> Alisia G</u>

Signature



Name